News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Santarus Inc. (SNTS) Initiates Phase IIa Study With SAN-300 In Patients With Active Rheumatoid Arthritis


12/23/2013 9:18:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS) today announced that it has begun patient enrollment in a multicenter, multinational, randomized, double-blind, placebo-controlled, multiple ascending dose study with the investigational drug SAN-300, its novel antibody that inhibits very late antigen-1 (VLA-1; a1ß1 integrin). The Phase IIa study is designed to evaluate the safety and tolerability of repeat subcutaneous (SC) doses of SAN-300 in patients with active rheumatoid arthritis (RA) with inadequate response to disease-modifying anti-rheumatic drugs (DMARDs). Approximately 90 patients will be enrolled in the study.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES